Funding research that can lead to breakthrough results.
The Children’s Cancer & Blood Foundation has helped the Division of Pediatric Hematology and Oncology at New York Presbyterian- Weill Cornell Medical Center become one of the most comprehensive programs of its kind. Our Division is part of the Department of Pediatrics at Weill Cornell Medicine, which means that our patients receive state-of-the-art diagnostic and treatment options across all specialties, and enables their physicians to work collaboratively for the highest level of care and the best possible outcomes.
Our Division treats children of all racial, ethnic and financial backgrounds who are affected by childhood cancers and blood disorders, from all parts of New York City and the surrounding area. Many of our patient families demonstrate financial need. Support from CCBF ensures that every child treated in the Division receives the best available care, regardless of their family’s ability to pay.
Led by Dr. Sujit Sheth, the Division sponsors the nation’s largest thalassemia clinic, the most extensive hemophilia center in metropolitan New York, and the largest center for Immune Thrombocytopenic Purpura, or ITP, a platelet disorder. Each year, hundreds of patients receive consultations and treatments during thousands of visits to the Division. The Division’s staff of board-certified pediatric specialists, skilled pediatric nurses, social workers, child life specialists, and an art therapist work tirelessly to provide the most advanced and individualized care possible.
The Division also educates young physicians and scientists in the subspecialty of pediatric hematology and oncology through a joint fellowship program with the Department of Pediatrics at Memorial Sloan Kettering Cancer Center. To date, more than 200 fellows have completed the program. These fellows have gone on to become leading physicians in treating pediatric cancer and blood diseases in the United States and around the world.
CCBF is funding brighter futures through its support of groundbreaking research in pediatric hematology and oncology in the Division. This funding is critical to making advances in diagnosing, treating, and curing pediatric cancer and blood diseases. Almost no funding for pediatric cancer drugs comes from pharmaceutical companies, and only 4% of United States government cancer research funding goes to study childhood cancer. Collaboration between our researchers and our clinicians means that investments in research result in advances in treatment options for our patients. Your contributions ensure that our patients have access to the best and most cutting-edge treatments, including clinical trials.
Thanks to the development of new medications and treatment strategies for many childhood cancers and blood disorders, our young patients are living longer than ever. As survival rates increase, the quality of life for these survivors (such as long term survivorship care and fertility preservation) has become an increasing concern and an important part of our new programs. We aim not only to treat these young patients but to return them to lives that are as normal and productive as possible.
Here are just a few of the projects our scientists are working on:
David Lyden is working to understand the role of tumor cell-derived “packages” called exosomes in cancer metastasis. By characterizing the exosomes, our scientists hope to be able to determine which cancers will spread—and to where.
Lisa Roth is studying the factors that lead to the development of lymphoma, with the goal of developing therapies that can target specific steps in this developmental cascade.
Nicole Kucine is studying genetic factors causing rare disorders in children called myeloproliferative syndromes.
Individuals with thalassemia develop transfusional iron overload and the iron may be deposited in organs and cause complications. The Comprehensive Thalassemia Program has focused on research related to defining the iron levels in the tissues and studying chelation therapy to effectively remove the iron that has been deposited and prevent more from accumulating.
The Hemophilia Treatment Center is participating in trials of newer agents to ameliorate and prevent bleeding in hemophilia patients, including potentially curative gene therapy approaches.
The platelet disorders program is studying factors that predispose children to have a more chronic pattern of disease with the goal of predicting this at diagnosis.
The Division has developed a treatment that rendered bone marrow transplant unnecessary for children and teenagers with Philadelphia-chromosome-positive acute lymphoblastic leukemia. Previously, transplant had been considered the standard of care for this disease.
Through the Onco-Fertility Program, our clinicians identify patients at high risk of impaired fertility from chemotherapy and offer fertility-preserving approaches.
In conjunction with the Adolescent and Young Adult Lymphoma Program, our researchers are designing targeted therapies that may have less toxicity than traditional chemotherapy for Hodgkin and Non-Hodgkin Lymphoma.
At the heart of the Division of Pediatric Hematology and Oncology is a team of specialty-trained physicians who provide innovative treatments to children with cancer and blood diseases.
To learn more about the Division’s doctors, or to schedule an appointment, visit weillcornell.org.